Plasma lipid transfer proteins

Current Opinion in Lipidology

Volumn 17, Issue 3, 2006, Pages 302-308

  Jiang, Xian Cheng ^a   Zhou, Hong Wen ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Gene knockout mice; HDL; LDL; Phospholipid transfer protein; Transgenic mice

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTERYL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPID TRANSFER PROTEIN; LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL SIZE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ENDOPLASMIC RETICULUM; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 33646891341     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998; 18:297-330.
2. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276:1861-1864.
3. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987; 327:632-634.
4. Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B 1982; 71:265-269.
5. Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem 1995; 270:17133-17138.
6. Day JR, Albers JJ, Lofton-Day CE, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem 1994; 269:9388-9391.
7. Guyard-Dangremont V, Desrumaux C, Gambert P, et al. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species: relation to atherogenesis susceptibility. Comp Biochem Physiol B Biochem Mol Biol 1998; 120:517-525.
8. Jauhiainen M, Setala NL, Ehnholm C, et al. Phospholipid transfer protein is present in human tear fluid. Biochemistry 2005; 4422:8111-8116. This study indicates the existence of PLTP in human tears and its possible function there.
9. Ponsin G, Qu SJ, Fan HZ, Pownall HJ. Structural and functional determinants of human plasma phospholipid transfer protein activity as revealed by site-directed mutagenesis of charged amino acids. Biochemistry 2003; 4215:4444-4451.
10. Oka T, Kujiraoka T, Ito M, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 2000; 41:1651-1657.
11. Murdoch SJ, Wolfbauer G, Kennedy H, et al. Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res 2002; 43:281-289.
12. Janis MT, Siggins S, Tahvanainen E, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res 2004; 4512:2303-2309.
13. Janis MT, Metso J, Lankinen H, et al. Apolipoprotein E activates the low activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 2005; 331:333-340. This study describes the possible role of apoE in promoting the transfer of a low-activity form of PLTP into a high-activity one.
14. Hayek T, Chajek-Shaul T, Walsh A, et al. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest 1992; 90:505-510.
15. Collet X, Tall AR, Serajuddin H, et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 1999; 40:1185-1193.
16. Gauthier A, Lau P, Zha X, et al. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005; 25:2177-2184. The study clearly indicated that, in vitro, CETP directly mediates HDL-CE liver delivery. This process is independent from SR-BI, LRP and LDLr.
17. Silver DL. A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in liver. J Biol Chem 2002; 277:34042-34047.
18. Willnow TE, Sheng Z, Ishibashi S, et al. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264:1471-1474.
19. Medh JD, Fry GL, Bowen SL, et al. The 39-kDa receptor-associated protein modulates lipoprotein catabolism by binding to LDL receptors. J Biol Chem 1995; 270:536-540.
20. van Haperen R, van Tol A, Vermeulen P, et al. Human plasma phospholipids transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20:1082-1088.
21. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipids transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103:907-914.
22. Qin S, Kawano K, Bruce C, et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res 2000; 41:269-276.
23. Yan D, Navab M, Bruce C, et al. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res 2004; 45:1852-1858.
24. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000; 105:513-520.
25. Masson D, Staels B, Gautier T, et al. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res 2004; 453:543-550.
26. Cao G, Beyer TP, Yang XP, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002; 277:39561-39565.
27. Groot PH, Pearce NJ, Yates JW, et al. Synthetic LXR agonists elevate LDL in CETP species. J Lipid Res 2005; 46:2182-2191. Study showed the effect of LXR agonist in monkey and hamster, both have CETP in the circulation.
28. Paromov VM, Morton RE. Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J Biol Chem 2003; 278:40859-40866.
29. Gautier T, Masson D, de Barros JP, et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem 2000; 275:37504-37509.
30. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/apoCI-knocked out mice. J Biol Chem 2002; 277:31354-31363.
31. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. Biochem J 2005; 385:189-195.
32. Dumont L, Gautier T, de Barros JP, et al. Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem 2005; 280:38108-38116. This study describes the detailed molecular mechanism of the inhibitory effect of apoC-I on CETP.
33. Bouly M, Masson D, Gross B, et al. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 2001; 276:25841-25847.
34. Urizar NL, Dowhan DH, Moore DD. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 2000; 275:39313-39317.
35. Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to glucose metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001; 50:1851-1856.
36. Oomen PH, van Tol A, Hattori H, et al. Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in type 1 diabetes mellitus. Diabet Med 2005; 22:768-774.
37. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
38. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004; 45:948-953.
39. Ayyobi AF, Hill JS, Molhuizen HO, et al. Cholesterol ester transfer protein (CETP) Taq1B polymorphism influences the effect of a standardized cardiac rehabilitation program on lipid risk markers. Atherosclerosis 2005; 181:363-369.
40. Hodoglugil U, Williamson DW, Huang Y, et al. An interaction between the TaqIB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high-density lipoprotein cholesterol levels in Turks. Turks Clin Genet 2005; 68:118-127.
41. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005; 111:278-287. Large, multicenter trial, demonstrating the effect of CETP TaqIB polymorphism on HDL, CAD and efficacy of statin therapy.
42. Mohrschladt MF, van der Sman-de Beer F, Hofman MK, et al. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet 2005; 13:877-882.
43. Frisdal E, Klerkx AH, Goff WL, et al. Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS study. Hum Mol Genet 2005; 14:2607-2618. This study describes the effect of functional interaction of three common CETP polymorphisms on plasma CETP levels.
44. Blankenberg S, Rupprecht HJ, Bickel C, et al. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:1983-1989.
45. Thompson JF, Durham LK, Lira ME, et al. CETP polymorphisms associated with HDL cholesterol may differ from those associated with cardiovascular disease. Atherosclerosis 2005; 181:45-53. The effect of CETP polymorphisms on HDL cholesterol and CAD may be different.
46. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23:1857-1862.
47. Yatsuya H, Tamakoshi K, Hattori H, et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J 2004; 68:11-16.
48. Desrumaux CM, Mak PA, Boisvert WA, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003; 44:1453-1461.
49. O'Brien KD, Vuletic S, McDonald TO, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 2003; 108:270-274.
50. Tan KC, Shiu SW, Wong Y, et al. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005; 178:365-370.
51. Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7:847-852.
52. Jiang XC, Li Z, Liu R, et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem 2005; 280:18336-18340. A possible mechanism by which PLTP deficiency causes apoB level reduction was evaluated in this study.
53. Jiang XC, Tall AR, Qin S, et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 2002; 277:31850-31856.
54. Schlitt A, Liu J, Yan D, et al. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 2005; 1733:187-191.
55. Van Haperen R, Van Tol A, Van Gent T, et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002; 277:48938-48943.
56. Yang XP, Yan D, Qiao C, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003; 23:1601-1607.
57. Lie J, De Crom R, Van Gent T, et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res 2002; 43:1875-1880.
58. Lie J, de Crom R, van Gent T, et al. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B containing lipoproteins. J Lipid Res 2004; 45:805-811.
59. Yamada T, Kawata M, Arai H, et al. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. Acta Neuropathol (Berl) 1995; 90:633-666.
60. Rodriguez E, Mateo I, Infante J, et al. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele. J Neurol 2005; 17 August [Epub ahead of print]. A relationship between CETP polymorphism and apoE4 in Alzheimer's patients was demonstrated.
61. Fidani L, Goulas A, Crook R, et al. An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease. Neurosci Lett 2004; 357:152-154.
62. Zhu H, Gopalraj RK, Kelly JF, et al. Lack of genetic association of cholesteryl ester transfer protein polymorphisms with late onset Alzheimers disease. Neurosci Lett 2005; 381:36-41.
63. Albers JJ, Wolfbauer G, Cheung MC, et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta 1995; 1258:27-34.
64. Krapfenbauer K, Yoo BC, Kim SH, et al. Differential display reveals downregulation of the phospholipid transfer protein (PLTP) at the mRNA level in brains of patients with Down syndrome. Life Sci 2001; 68:2169-2179.
65. Vuletic S, Jin LW, Marcovina SM, et al. Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res 2003; 44:1113-1123.
66. Vuletic S, Peskind ER, Marcovina SM, et al. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases: PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res 2005; 80:406-413. This study indicated that CSF PLTP activity in Alzheimer's patients is actually decreased. Moreover, the study also showed that PLTP induces apoE secretion in primary human astrocytes in vitro, providing the connection between brain PLTP and Alzheimer's disease.
67. Desrumaux C, Risold PY, Schroeder H, et al. Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB J 2005; 19:296-297. Mouse PLTP deficiency results in significant depletion of brain vitamin E levels. This is associated with increased anxiety in mice.
68. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406:203-207.
69. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515.